Cleveland Clinic Pulmonary Hypertension Summit 2025

+ Include: 5 videos + 5 audios + 5 file sub vtt + 36 pdfs, size: 8.48 GB

+ Target Audience: physicians, physician’s assistants interest in pulmonary hypertension

+ Information:

The 2025 Pulmonary Hypertension Summit will provide you with an overview of the practical issues in the diagnosis, evaluation, and management of patients with pulmonary hypertension. Expert speakers will present the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients. Faculty will present on advances in diagnosis and risk stratification, emerging therapeutics, management of populations with concomitant disease, and technological innovations. Take advantage of this unique opportunity, either in-person or via live stream.

New in 2025: Hands-on Workshops!  Participants will join our Cleveland Clinic experts for interactive, experiential training to develop a fuller appreciation of PAH diagnosis and management.  Space is limited, so register today!

By attending, you will be able to:

• Demonstrate optimal procedures for right heart catheterization, echocardiography, and cardiopulmonary exercise tests.
• Detail the evidence base and clinical use of risk assessment tools and treatment algorithms for diagnosing, classifying, and treating pulmonary arterial hypertension.
• Critically review the pharmacologic profile, efficacy and side effect data, and clinical indications for sotatercept and discuss its role in treating pulmonary arterial hypertension.
• Summarize research advances in the pathobiology, diagnosis, and treatment of pulmonary hypertension as well as clinical trial design.
• Describe the diagnosis and management of concomitant conditions that occur in patients with pulmonary hypertension, including chronic lung disease, heart failure, right ventricular dysfunction, connective tissue disease, and thromboembolic pulmonary hypertension.

Who Should Attend?

The Summit is directed to physicians, physician’s assistants, nurse practitioners, nurses, and pharmacists with an interest in pulmonary hypertension.

+ Topics:

• Session I Moderator: Roger Alvarez
• 1:10 PM PH Definition and Classification – How do I deal with Comorbidities? David Badesch
• 1:40 PM Risk Stratification in PAH – what is new? Raymond Benza
• 2:10 PM Updated PAH Treatment Algorithm Vallerie McLaughlin
• 2:40 PM Exhibit Break
• 3:00 PM The new kid on the (treatment) block – Sotatercept for PAH David Badesch
• 3:30 PM Panel Discussion: Put it all together Moderator: Roger Alvarez Panel: David Badesch, Raymond Benza, Vallerie McLauglin
• 4:30 PM Adjourn

Friday, January 17 All times in Eastern Time

• Session II Moderator: Adriano Tonelli
• 8:00 AM Update in Pathobiology and future novel pathways Marc Humbert
• 8:30 AM Future of clinical trial design Vallerie McLaughlin
• 9:00 AM Panel Discussion Marc Humbert, Vallerie McLaughlin
• 9:30 AM Exhibit Break
• Session III Moderator: Alice Goyanes
• 10:00 AM CTEPH Updates from the World Symposium Nick Kim
• 10:30 AM Panel Discussion Moderator: Alice Goyanes Cases – Michael Tong, Ihab Haddadin, Nick Kim
• 11:30 AM Non-CME Satellite Lunch & Exhibits
• Session IV Moderator: Samar Farha
• 12:30 PM PH in Chronic Lung Disease Oksana Shlobin
• 1:00 PM What is novel in HFpEF- PH? Raymond Benza
• 1:30 PM PH and RV failure in the ICU Adriano Tonelli
• 2:00 PM Panel Discussion Moderator: Samar Farha Oksana Shlobin, Raymond Benza, Adriano Tonelli
• 2:30 PM Exhibit Break
• Session V Moderator: David Zisman
• 3:00 PM CTD PH Stephen Mathai
• 3:30 PM Patient Perspective Jimmy Ford
• 4:00 PM Panel Discussion Moderator: Anthony Cucci Stephen Mathai, Jimmy Ford, Mindy Rivera
• Session VI Moderator: Gustavo Heresi
• 4:15 PM Keynote: PH: Past, Present, and Future Marc Humbert
• 5:00 PM Closing remarks and Adjourn Gustavo Heresi